✦ LIBER ✦

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

✍ Scribed by Shaji K. Kumar; Martha Q. Lacy; Suzanne R. Hayman; Keith Stewart; Francis K. Buadi; Jacob Allred; Kristina Laumann; Philip R. Greipp; John A. Lust; Morie A. Gertz; Steven R. Zeldenrust; P. Leif Bergsagel; Craig B. Reeder; Thomas E. Witzig; Rafael Fonseca; Stephen J. Russell; Joseph R. Mikhael; David Dingli; S. Vincent Rajkumar; Angela Dispenzieri

Book ID: 101433643
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 286 KB
Volume: 86
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.22053

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A comparison of lenalidomide/dexamethaso

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

✍ Meaghan L. Khan; Craig B. Reeder; Shaji K. Kumar; Marthy Q. Lacy; Donna E. Reece 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

Bortezomib, dexamethasone, cyclophospham

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

✍ Kumar, S K; Flinn, I; Noga, S J; Hari, P; Rifkin, R; Callander, N; Bhandari, M; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 302 KB

Cyclophosphamide, bortezomib and dexamet

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

✍ Reeder, C B; Reece, D E; Kukreti, V; Chen, C; Trudel, S; Hentz, J; Noble, B; Pir 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 141 KB

A Phase II trial of pegylated liposomal

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients

✍ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop

Pegylated liposomal doxorubicin, vincris

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma : A Phase III multicenter randomized trial

✍ Robert M. Rifkin; Stephanie A. Gregory; Ann Mohrbacher; Mohamad A. Hussein 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame